cbdMD (YCBD) Return on Capital Employed (2017 - 2025)
cbdMD (YCBD) reported Return on Capital Employed of 28.37% for Q4 2025, up 9506.0% on a YoY basis from 0.3% in Q4 2024, and up 8.64% sequentially from 31.05% in Q3 2025.
cbdMD (YCBD) Return on Capital Employed (2017 - 2025) Analysis & Trends
cbdMD (YCBD) has 9 years of Return on Capital Employed data on file, last reported at 28.37% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 9506.0% year-over-year to 28.37%; the trailing twelve-month figure through Dec 2025 stood at 28.37% (up 9506.0% YoY), and the FY2025 full-year result was 29.6%, up 3990.0% from the prior year.
- Return on Capital Employed grew to 28.37% in Q4 2025, from 31.05% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 10.2% in Q1 2021 to a low of 287.32% in Q2 2024.
- A 5-year average of 104.41% and a median of 92.54% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed tumbled 21043 bps in 2024 and surged 26107 bps in 2025, its largest moves.
- Tracing YCBD's Return on Capital Employed over 5 years: stood at 40.82% in 2021, then plunged by 328 bps to 174.78% in 2022, then slipped by 15 bps to 201.66% in 2023, then jumped by 39 bps to 123.43% in 2024, then surged by 77 bps to 28.37% in 2025.
- Business Quant data shows YCBD's Return on Capital Employed at 28.37% in Q4 2025, 31.05% in Q3 2025, and 26.25% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | cbdMD | 438,678.80 | -2.95 Mn | 3.00 Mn | -28.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -28.37% |
| Sep 30, 2025 | -31.05% |
| Jun 30, 2025 | -26.25% |
| Mar 31, 2025 | -92.85% |
| Dec 31, 2024 | -123.43% |
| Sep 30, 2024 | -92.24% |
| Jun 30, 2024 | -287.32% |
| Mar 31, 2024 | -249.27% |
| Dec 31, 2023 | -201.66% |
| Sep 30, 2023 | -112.93% |
| Jun 30, 2023 | -76.89% |
| Mar 31, 2023 | -178.37% |
| Dec 31, 2022 | -174.78% |
| Sep 30, 2022 | -179.18% |
| Jun 30, 2022 | -101.38% |
| Mar 31, 2022 | -48.51% |
| Dec 31, 2021 | -40.82% |
| Sep 30, 2021 | -17.32% |
| Jun 30, 2021 | -15.36% |
| Mar 31, 2021 | -10.20% |